Table 2.
Costs and effects of changing the ANC cutoff line (500/mm3–1000/mm3–1500/mm3) in Japan and the UK.
| Cutoff line | Cost/QALYs | JPN | UK | ||
|---|---|---|---|---|---|
| HLA-guided treatment schedule | general treatment schedule without HLA test | HLA-guided treatment schedule | general treatment schedule without HLA test | ||
| 500/mm3 | Cost per patient £ | 16,257 (16,255–16,258) | 16,173 | 4021 (4008–4023) | 3,928 |
| QALYs for ten years | 6.27343 (6.27389–6.27334) | 6.27316 | 5.85539 (5.85672–5.85512) | 5.85459 | |
| ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test | 307,957 (111,753–464,946) | 116,190 (37,712–178,986) | |||
| 1000/mm3 | Cost per patient £ | 16,401 (16,377–16,405) | 16,329 | 4151 (4119–4157) | 4070 |
| QALYs for ten years | 6.25207 (6.25607–6.25126) | 6.24967 | 5.84267 (5.84698–5.84198) | 5.84062 | |
| ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test | 29,836 (7444–47,810) | 39,512 (8958–63,968) | |||
| 1500/mm3 | Cost per patient £ | 16,552 (16,517–16,558) | 16,487 | 4281 (4230–4291) | 4211 |
| QALYs for 10 years | 6.22917 (6.23434–6.22813) | 6.22608 | 5.8299 (5.83533–5.82882) | 5.82665 | |
| ICER £/ (QALY): HLA-guided treatment schedule vs. general treatment schedule without HLA test | 21,024 (3729–34,920) | 21,343 (2145–36,715) | |||
The numbers in the parentheses indicates results from the sensitivity analysis for CIAG prevention rate (80–20%).
JPN Japan, UK United Kingdom, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, CIAG Clozapine-induced agranylocytosis/granulocytopenia.